Clinical-stage focus ZyVersa is a clinical-stage biopharma leveraging two licensed proprietary platforms targeting renal and inflammatory diseases, signaling opportunities to partner or co-develop with a focus on late-stage clinical milestones and companion diagnostics.

Lead candidates VAR 200 targets cholesterol efflux in the kidney filtration system, presenting a clear nephrology expansion angle for nephrology networks, academic centers, and dialysis-focused entities seeking disease-modifying options.

Inflammasome IC 100 IC 100 addresses broad inflammatory pathways with potential for obesity-related and metabolic inflammatory conditions, suggesting cross-therapy partnerships with metabolic clinics, pharma in obesity cardiometabolic space, and CROs for trial support.

Funding momentum The company has secured multiple funding rounds and strategic partnerships, signaling ongoing capital availability for clinical development, potential for co-development deals, and revenue-sharing models to accelerate milestones.

Market positioning With revenue in the low tens of millions and a small-to-mid-sized team, ZyVersa presents a collaborative, agile profile suitable for BD partnerships, licensing deals, and strategic alliances with mid-cap pharma seeking pipeline diversification.